by Julia Samuel on  May 10, 2016 at 10:32 PM Diabetes News
A potential new intraocular treatment based on manipulating the renin angiotensin system (RAS) that both prevents and reverses some characteristics of diabetic retinopathy in a mouse model has been described in a report in The American Journal of Pathology.

Pathologic changes of the retina caused by diabetes is the leading cause of blindness in working adults. Diabetic retinopathy has no known cure, treatment options are inadequate, and prevention strategies offer limited protection.
Newly Introduced Intraocular Therapy for Diabetic Retinopathy
Newly Introduced Intraocular Therapy for Diabetic Retinopathy

"We are not aware of another study that has demonstrated a therapy capable of reversing this form of retinal pathology, particularly in the presence of persistent untreated hyperglycemia," commented lead investigator Maria B. Grant, MD, of the Eugene and Marilyn Glick Eye Institute of Indiana University, Indianapolis, IN.

"This research is based on the hypothesis that an imbalance between two axes of the RAS is a key initial event that leads to development of diabetic microvascular complications," explained Dr. Grant. The two axes consist of the classic and vasoprotective RAS.

The proinflammatory, vasoconstrictive classical RAS component is normally kept in check by a vasoprotective axis that is both anti-inflammatory and vasodilatory. Angiotensin converting enzyme-2 (ACE-2) is the primary enzyme of the vasoprotective component.

Administration of AAV-ACE--the therapeutic agent under evaluation--directly into the vitreous cavity of the eye using an adeno-associated virus vector, increases ACE-2 expression.

Investigators used mice, some of which were injected with streptozotocin (STZ) to induce diabetes. The protective effects of AAV-ACE2 were examined by performing two sets of experiments. In one cohort, AAV-ACE2 was administered two weeks prior to STZ injection. In a second cohort, to evaluate whether the enhanced expression of ACE2 could reverse diabetic retinopathy, AAV-ACE2 was administered six months after STZ, when diabetes and retinopathy were already established.

The investigators found that both strategies effectively decreased the numbers of proinflammatory cells present in the diabetic retina. Leukostasis--abnormal aggregation and clumping of white blood cells within blood vessels--was only seen in diabetic animals receiving control injections.

In addition, using a histological endpoint of retinal vascular degeneration, called acellular capillaries, the group determined that the AAV-ACE2 injection could reverse the diabetes-induced pathology. "These findings are very exciting because it is traditionally believed that this endpoint of vascular degeneration, acellular capillaries, represents an irreversible lesion," emphasized Dr. Grant.

One strength of this experimental approach is that intravitreal administration eliminates the problem of the blood-retinal barrier interfering with access of systemically-administered therapeutic agents. The investigators envision that inducing ACE2 overexpression to improve vascular characteristics and decrease inflammation may be translatable to other vascular diseases such as stroke, kidney disease, and heart disease.

Source: Eurekalert

Most Popular on Medindia